Acorda Therapeutics acquires Neuronex Acorda Therapeutics, Inc. today announced that the Company has finished the acquisition of Neuronex, Inc., a privately held company developing a nasal spray formulation of diazepam. Under the conditions of the agreement, Acorda paid $6.8 million to Neuronex to complete the acquisition. Diazepam Nasal Spray can be an important addition to your pipeline and aligns with this core strategy to develop and commercialize products that offer unique benefits to people who have neurological diseases, stated Ron Cohen, M.D., Acorda's CEO and President.I’d not spend that cash, because the benefit doesn’t seem worthwhile, says Svensson, 80, a former corporate financing officer from Bedford, Mass. 60 Minutes : The price of Dying His supplemental Medicare program is paying while the national federal government decides whether fundamental Medicare will cover Provenge and for whom. The tab for taxpayers could possibly be huge – prostate is the most common tumor in American men. Most of anyone who has it shall be eligible for Medicare, and Provenge will be an option for many late-stage cases. A gathering to consider Medicare insurance is defined for Nov. 17. I don’t know how they will deal with that sort of concern, stated Svensson, who was simply treated at the Lahey Clinic Medical Center in suburban Boston.